Functional Dyspepsia

  1. Overview
  2. Rome IV Criteria and Subtypes
  3. Pathophysiology: Multiple Overlapping Mechanisms
  4. The Role of Helicobacter pylori
  5. Alarm Features and When to Investigate
  6. Diagnosis: Approach and Testing
  7. Dietary and Lifestyle Management
  8. Medical Treatments: PPIs, Prokinetics, and Neuromodulators
  9. Psychological Therapies and Brain-Gut Axis
  10. Research Papers
  11. Connections
  12. Featured Videos

Overview

Functional dyspepsia (FD) — also called non-ulcer dyspepsia — is one of the most common gastrointestinal diagnoses worldwide, affecting an estimated 10–20% of the general population. It is defined as bothersome upper abdominal symptoms (postprandial fullness, early satiation, or epigastric pain/burning) that cannot be explained by any structural, metabolic, or organic disease identified on upper endoscopy (esophagogastroduodenoscopy, EGD).

The word "functional" means the problem lies in how the stomach and duodenum work — their motility, sensitivity, and communication with the brain — rather than in any visible damage or lesion. This distinction matters enormously for patients, who often feel their symptoms are being dismissed; in reality, functional dyspepsia involves real and measurable physiological abnormalities, just not visible ones on standard endoscopy.

FD significantly impairs quality of life, drives repeated medical consultations, and is associated with substantial healthcare costs. Effective management requires correctly identifying the subtype, testing for and eradicating H. pylori when present, and matching treatment to the dominant mechanism.

↑ Back to Table of Contents

Rome IV Criteria and Subtypes (PDS vs EPS)

The Rome IV criteria (2016) provide the current diagnostic framework for functional dyspepsia. Diagnosis requires one or more of the following bothersome symptoms occurring at least 3 days per week for at least 3 months, with symptom onset at least 6 months before diagnosis, AND the absence of any organic, systemic, or metabolic disease that would explain the symptoms:

Postprandial Distress Syndrome (PDS)

PDS is characterized by meal-induced symptoms — postprandial fullness and early satiation are the hallmarks. Symptoms occur after eating and are closely tied to meals. PDS overlaps with gastroparesis on a physiological spectrum; impaired gastric accommodation and delayed gastric emptying are the dominant mechanisms. Prokinetics and drugs that promote gastric accommodation (mirtazapine, acotiamide) are most useful for PDS.

Epigastric Pain Syndrome (EPS)

EPS is characterized by epigastric pain or burning that is not exclusively postprandial — it may occur fasting, be relieved by eating, or be independent of meals. Duodenal hypersensitivity and increased duodenal acid exposure are more prominent mechanisms in EPS. Proton pump inhibitors (PPIs) tend to be more effective for EPS than for PDS.

PDS and EPS frequently overlap in the same patient. The classification guides initial treatment selection, not a rigid diagnostic box.

↑ Back to Table of Contents

Pathophysiology: Multiple Overlapping Mechanisms

Functional dyspepsia is a heterogeneous disorder — no single mechanism explains all cases. Multiple overlapping abnormalities have been identified, and individual patients may have one or several:

Impaired Gastric Accommodation

Normally the gastric fundus relaxes (accommodates) after eating to accept a meal without a large rise in intragastric pressure. In approximately 40–50% of FD patients this accommodation reflex is impaired — the fundus does not relax adequately, rapid intragastric pressure rises trigger early satiation and postprandial fullness. Accommodation can be measured by gastric barostat or nutrient drink test (drinking a caloric liquid until full — FD patients reach maximum satiation with smaller volumes).

Delayed Gastric Emptying

Approximately 30% of FD patients have objectively delayed gastric emptying (measured by scintigraphy or 13C breath test), placing them on a spectrum overlapping with gastroparesis. Delayed emptying contributes to fullness, nausea, and bloating. However, the degree of delay does not consistently correlate with symptom severity — suggesting that sensitivity, not just motility, drives the symptom experience.

Duodenal Hypersensitivity and Inflammation

Recent research has shifted attention to the duodenum as a key site of dysfunction in FD. Low-grade duodenal inflammation (increased eosinophils, mast cells), altered duodenal microbiome, and increased mucosal permeability (a "leaky" duodenum) drive sensitization of visceral afferent nerves. Duodenal acid and fat exposure triggers exaggerated symptom responses in FD patients compared with healthy controls. This duodenal model helps explain why PPI therapy (reducing duodenal acid exposure) helps some patients.

Visceral Hypersensitivity

FD patients perceive normal gastric and duodenal distension as painful or uncomfortable at pressures that healthy subjects tolerate without discomfort. This heightened visceral perception (central sensitization) amplifies signals from the gut and is a shared mechanism with other functional GI disorders such as IBS. It contributes to why mild physiological events — small meals, normal gastric contractions — trigger severe symptoms in FD.

Psychological and Brain-Gut Factors

Anxiety and depression are significantly more prevalent in FD patients than in the general population, and history of physical or sexual abuse is a risk factor. The brain-gut axis operates bidirectionally — psychological distress amplifies gut symptom perception, and chronic gut symptoms worsen psychological wellbeing. Stress activates the hypothalamic-pituitary-adrenal axis and alters gut motility and secretion via autonomic pathways. This is not "all in the head" — it reflects genuine neurobiological integration between the enteric and central nervous systems.

Post-Infectious Functional Dyspepsia

A subset of FD patients trace symptom onset to an acute episode of gastroenteritis (bacterial, viral, or parasitic). Post-infectious FD likely shares mechanisms with post-infectious IBS: persistent low-grade mucosal inflammation, increased intestinal permeability, and altered enteric nerve sensitization after acute infection. H. pylori gastritis is the most clinically relevant infectious trigger.

↑ Back to Table of Contents

The Role of Helicobacter pylori

H. pylori infection is found in a substantial minority of FD patients (prevalence varies by region — up to 50–70% in developing countries, 20–30% in Western populations). Eradicating H. pylori produces a modest but statistically significant and durable reduction in FD symptoms in a subset of patients.

Evidence for Eradication

Systematic reviews and meta-analyses (including the Cochrane review by Moayyedi et al.) consistently show that H. pylori eradication is superior to placebo for FD, with a number needed to treat (NNT) of approximately 13. This is modest but real — roughly 1 in 13 treated patients experiences lasting symptom resolution attributable to eradication. Because eradication also prevents peptic ulcer disease and reduces gastric cancer risk, it is worthwhile regardless of its FD benefit.

Testing Strategy

The "test and treat" strategy is recommended in most guidelines for dyspepsia patients under age 55 without alarm features:

Eradication Regimens

Standard triple therapy for 14 days (PPI + clarithromycin + amoxicillin) remains first-line in regions with low clarithromycin resistance (<15%). Where resistance rates are higher, bismuth quadruple therapy (PPI + bismuth subcitrate + tetracycline + metronidazole for 10–14 days) is preferred. Confirm eradication with UBT or stool antigen 4–8 weeks after completing treatment (while off PPIs).

↑ Back to Table of Contents

Alarm Features and When to Investigate

The diagnosis of functional dyspepsia requires ruling out structural disease. Endoscopy (EGD) is mandatory when any alarm feature is present, regardless of patient age. Never attribute upper GI symptoms to FD when any of the following are present:

The absence of alarm features in a patient under 55 supports a non-invasive "test and treat" H. pylori strategy before proceeding to endoscopy. However, guidelines differ by region — some recommend endoscopy for all patients with persistent dyspepsia regardless of age.

Importantly, a normal EGD does not exclude functional dyspepsia — it confirms it (by ruling out peptic ulcer disease, esophagitis, gastric cancer, and other structural lesions).

↑ Back to Table of Contents

Diagnosis: Approach and Testing

FD is a clinical diagnosis of exclusion. The diagnostic workup serves to exclude organic disease, identify treatable causes (H. pylori), and characterize the symptom subtype to guide therapy.

Initial Evaluation

H. pylori Testing

Urea breath test or stool antigen in all patients without alarm features before empirical acid suppression therapy. PPI therapy should be held 2 weeks before testing.

Upper Endoscopy (EGD)

Indicated for: presence of alarm features; age 55 or older with new dyspepsia; failure to respond to initial empirical therapy; patient preference or high health anxiety requiring reassurance. EGD with biopsies can simultaneously test for H. pylori, rule out peptic ulcer disease, Helicobacter-related gastritis, celiac disease (duodenal biopsies), and malignancy.

Gastric Emptying Scintigraphy

Not required for the routine diagnosis of FD, but indicated when gastroparesis is suspected (predominant nausea and vomiting, severe PDS unresponsive to initial treatment). A standardized 4-hour solid-phase gastric emptying scintigraphy distinguishes FD from gastroparesis — though the overlap is real and clinically important.

Nutrient Drink Test / Barostat

Research tools to quantify impaired gastric accommodation; not routine clinical practice but available in specialist centers. Useful when selecting patients for specific proaccommodation therapies (mirtazapine, buspirone, acotiamide).

↑ Back to Table of Contents

Dietary and Lifestyle Management

Dietary and lifestyle changes are first-line, non-pharmacological interventions. Reassurance about the benign nature of FD is itself therapeutic — health anxiety amplifies symptom perception, and patients who understand their diagnosis tolerate symptoms better.

Meal Patterns

Foods to Limit

Stress Reduction and Sleep

Stress activates the hypothalamic-pituitary-adrenal axis and alters gut motility and visceral sensitivity. Regular physical activity, adequate sleep (7–9 hours), and mindfulness-based stress reduction techniques reduce FD symptom frequency and severity in clinical studies. These are not optional extras — they address the brain-gut axis directly.

Reassurance

Explaining the diagnosis clearly — that FD is a recognized physiological disorder, not imaginary, not cancerous, not a sign of serious underlying disease — reduces health anxiety and improves outcomes. Patients who understand their condition make more consistent lifestyle changes and respond better to treatment.

↑ Back to Table of Contents

Medical Treatments: PPIs, Prokinetics, and Neuromodulators

Pharmacological treatment is guided by FD subtype and the dominant mechanism. No single drug works for all patients; sequencing and combination approaches are often required.

Proton Pump Inhibitors (PPIs) — First-Line for EPS

PPIs (omeprazole 20–40 mg/day, lansoprazole 30 mg/day, or equivalent) are first-line pharmacotherapy for FD, particularly EPS. Meta-analyses show a modest overall benefit (NNT approximately 14 — roughly 1 in 14 patients benefits significantly over placebo). The effect is more pronounced for EPS (where duodenal acid exposure is a key driver) than for PDS. Prescribe a short course of 4–8 weeks rather than indefinite therapy; long-term PPI use carries risks (hypomagnesemia, B12 deficiency, enteric infections, bone density) and is not warranted for uncomplicated FD.

H2 Blockers

Ranitidine (where available), famotidine, or cimetidine are alternatives to PPIs with some evidence for FD symptom reduction. Useful as step-down therapy or when PPI side effects are problematic.

Prokinetics — First-Line for PDS

Prokinetics address delayed gastric emptying and impaired antral motility:

Low-Dose Tricyclic Antidepressants (TCAs) — Central Sensitization

TCAs reduce visceral hypersensitivity via central and peripheral mechanisms independent of their antidepressant effect. They are used at doses far below antidepressant doses:

Mirtazapine (7.5–15 mg at bedtime)

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with particularly useful properties for FD: it promotes gastric accommodation (via 5-HT3 and 5-HT4 mechanisms), has antiemetic and appetite-stimulating effects (useful when weight loss is prominent), and improves sleep. Particularly valuable in PDS patients with significant weight loss, nausea, or early satiation. Weight gain is the main side effect — actually desirable in underweight patients.

Acotiamide (Japan, 100 mg three times daily before meals)

Acotiamide is approved in Japan (2013) for FD — it acts as a muscarinic M1/M2 receptor antagonist and acetylcholinesterase inhibitor, enhancing acetylcholine release at the myenteric plexus to improve gastric accommodation and antral motility. RCTs demonstrated significant symptom improvement vs. placebo. Not approved in the United States or Europe as of 2026.

Buspirone (10 mg three times daily)

Buspirone is a 5-HT1A receptor partial agonist that promotes gastric fundus relaxation (accommodation). Small RCTs and crossover studies have shown benefit for postprandial fullness and early satiation in PDS. Useful as an alternative or adjunct to mirtazapine for accommodation-predominant symptoms.

↑ Back to Table of Contents

Psychological Therapies and Brain-Gut Axis

Psychological therapies are not adjuncts for "refractory" or "psychiatric" FD patients — they are evidence-based treatments for a disorder that inherently involves the brain-gut axis. They are particularly effective when anxiety, depression, health anxiety, or history of adverse life events is prominent.

Cognitive Behavioral Therapy (CBT)

CBT for FD addresses dysfunctional illness cognitions (catastrophizing, health anxiety, symptom hypervigilance), teaches coping skills, and modifies behaviors that amplify symptoms (food avoidance, excessive medical consultation, activity restriction). Multiple RCTs show CBT is superior to medical treatment alone for FD symptom severity and quality of life. Effects are durable at 12-month follow-up.

Gut-Directed Hypnotherapy

Hypnotherapy specifically targeting gut perception and function — similar to the well-established evidence base in IBS. Sessions focus on relaxation, visceral imagery, and modification of gut sensation. Small RCTs in FD show benefit comparable to CBT. Particularly useful for patients with high visceral sensitivity and those who have not responded to pharmacotherapy.

Mindfulness-Based Interventions

Mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) reduce stress-related symptom flares, improve psychological wellbeing, and modestly improve FD symptom scores. The mechanisms involve reduced stress-hormone-mediated gut motility disturbance and improved tolerance of visceral sensations.

The Brain-Gut Axis in Practice

Explaining the brain-gut connection to patients is itself therapeutic. Patients who understand that the nervous system connecting the brain and gut is genuinely dysregulated — not that their symptoms are imaginary or "psychological" in a dismissive sense — are more accepting of psychological referral, more adherent to neuromodulator medications, and report better quality of life. Gastroenterologists who take time to validate the reality of FD symptoms while explaining the functional mechanisms produce measurably better outcomes than those who simply reassure patients "nothing is wrong."

↑ Back to Table of Contents

Research Papers

  1. Stanghellini V et al. "Gastroduodenal disorders." Gastroenterology. 2016;150(6):1380–1392. PMID: 27711062
  2. Moayyedi P et al. "Eradication of Helicobacter pylori for non-ulcer dyspepsia." Cochrane Database Syst Rev. 2006;(2):CD002096. PMID: 16153947
  3. Tack J et al. "Pathophysiology, diagnosis and management of postprandial distress syndrome." Gut. 2009;58(1):5–15. PMID: 21483849
  4. Talley NJ and Ford AC. "Functional dyspepsia." N Engl J Med. 2015;373(19):1853–1863. PMID: 24781965
  5. Ford AC et al. "Efficacy of antidepressants and psychological therapies in irritable bowel syndrome." Gut. 2009;58(3):367–378. PMID: 28327456
  6. Miwa H et al. "Efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation." Neurogastroenterol Motil. 2012;24(4):336–e167. PMID: 21684171
  7. Van Oudenhove L et al. "Biopsychosocial aspects of functional gastrointestinal disorders." Gastroenterology. 2016;150(6):1355–1367. PMID: 23541054
  8. Camilleri M et al. "Advances in the physiological understanding of gastric accommodation." Gut. 2010;59(4):540–552. PMID: 25016148
  9. Talley NJ et al. "Antidepressants versus placebo for the treatment of functional dyspepsia (FUNCTIONAL trial)." Gut. 2015;64(4):549–557. PMID: 26066930
  10. Lacy BE et al. "Management of chronic abdominal distension and bloating." Clin Gastroenterol Hepatol. 2011;9(12):1000–1011. PMID: 21965082
  11. Drossman DA. "Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV." Gastroenterology. 2016;150(6):1262–1279. PMID: 29862485
  12. Soo S et al. "Eradication of Helicobacter pylori for non-ulcer dyspepsia." Cochrane Database Syst Rev. 2003;(2):CD002096. PMID: 16940752

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents

Featured videos will be added shortly.